Xeris Biopharma (NASDAQ:XERS) Sets New 52-Week High Following Analyst Upgrade

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) hit a new 52-week high on Wednesday after Barclays raised their price target on the stock from $14.00 to $18.00. Barclays currently has an overweight rating on the stock. Xeris Biopharma traded as high as $16.35 and last traded at $16.2060, with a volume of 277,899 shares changing hands. The stock had previously closed at $15.83.

A number of other research analysts have also recently issued reports on the stock. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. HC Wainwright raised their target price on Xeris Biopharma from $10.00 to $18.00 and gave the company a “buy” rating in a report on Friday, November 6th. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, November 4th. Finally, Oppenheimer reissued an “outperform” rating and set a $21.00 price target (up from $18.00) on shares of Xeris Biopharma in a report on Friday, November 6th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xeris Biopharma presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Insiders Place Their Bets

In related news, insider Beth Hecht sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total value of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This represents a 2.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $12.49, for a total transaction of $312,250.00. Following the transaction, the insider directly owned 1,559,208 shares of the company’s stock, valued at $19,474,507.92. This represents a 1.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 168,332 shares of company stock valued at $1,678,971 in the last ninety days. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma News Roundup

Here’s some of the latest news about XERS:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $18 price target while raising its earnings forecasts: FY2026 EPS to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The higher longer-term outlook suggests improved expectations for earnings growth. Xeris Biopharma coverage
• Positive Sentiment: Wall Street Zen upgraded Xeris, and a separate brokerage roundup characterized the stock’s consensus rating as “Moderate Buy.” These ratings add to the favorable analyst tone. Wall Street Zen upgrade Brokerage ratings
• Neutral Sentiment: The short-interest item calls the change a “large increase” but reports zero shares short as of November 10. Because those details conflict, it offers no clear signal about short-selling pressure or potential short covering.

Institutional Trading of Xeris Biopharma

Large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new position in Xeris Biopharma in the 2nd quarter valued at about $115,042,000. Wellington Management Group LLP lifted its holdings in shares of Xeris Biopharma by 8.9% in the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock valued at $18,732,000 after purchasing an additional 193,749 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $15,941,000. Parkman Healthcare Partners LLC purchased a new position in shares of Xeris Biopharma during the second quarter valued at approximately $14,316,000. Finally, Algert Global LLC grew its holdings in Xeris Biopharma by 50.6% during the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock worth $13,804,000 after buying an additional 585,984 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Xeris Biopharma Price Performance

The firm has a market cap of $2.95 billion, a P/E ratio of -321.80 and a beta of 0.61. The company has a fifty day moving average of $9.92 and a 200-day moving average of $7.70. The company has a debt-to-equity ratio of 3.89, a current ratio of 2.15 and a quick ratio of 1.02.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. On average, sell-side analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.